Biogen
NEWS
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Researchers with the University of Cambridge in the UK for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.
The annual Clinical Trials on Alzheimer’s Disease conference is scheduled for November 9-12, and Biogen plans to present data on its portfolio, including its controversial Aduhelm.
Collaboration is key to faster breakthroughs. The NIH, FDA, and 15 private organizations have announced they are joining forces for the sake of the 30 million Americans suffering from a rare disease.
Although the literature suggests this condition may affect 200 people globally, Williams and his team think the numbers are higher.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
It was yet another busy week for clinical trial news. Here’s a look.
More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival.
Biogen’s Aduhelm (aducanumab) reported only $300,000 in third-quarter sales compared to original analyst average estimates of $10.79 million.
JOBS
IN THE PRESS